Stoke Therapeutics (STOK) to Release Quarterly Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK) is projected to release its earnings data before the market opens on Monday, March 24th. Analysts expect Stoke Therapeutics to post earnings of ($0.56) per share and revenue of $4.20 million for the quarter.

Stoke Therapeutics Trading Up 6.0 %

STOK opened at $8.60 on Monday. The company has a market capitalization of $455.52 million, a PE ratio of -4.10 and a beta of 0.99. Stoke Therapeutics has a 1-year low of $5.60 and a 1-year high of $17.58. The firm’s 50 day simple moving average is $9.57 and its two-hundred day simple moving average is $11.61.

Wall Street Analyst Weigh In

Several brokerages have recently commented on STOK. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. HC Wainwright raised their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.